SFRP1 protein concentration was significantly higher in tumour samples from patients with clinical stage T4 compared to NSCLC samples with other T parameters: T1 vs. T4 (126.84 vs. 1790.35; p = 0.008), T2 vs. T4 (200.85 vs. 1790.35; p = 0.002), and T3 vs. T4 (208.83 vs. 1790.35; p = 0.012), respectively. This evidence concerns the gene SFRP1 and neoplasm.